Recent

% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

  • larrystone13 larrystone13 Feb 1, 2013 11:48 AM Flag

    2/1/13 Seeking " SRPT Developing It's Own Antisense " LINK

    Isis: FDA Approval Of Kynamro Promises A Bright Future For Company
    February 1, 2013 By: Prohost Biotech
    In addition to Isis and alnylam, Sarepta (SRPT), which used to be known by the name AVI Pharmaceuticals, is developing its own proprietary far-reaching antisense molecule therapeutics. A few months ago, the firm unveiled results of its lead product eteplirsen for Duchene muscular dystrophy. The drug demonstrated a successful production of dystrophin, a rod-shaped cytoplasmic protein and a vital part of a protein complex that connects the cytoskeleton of a muscle fiber to the surrounding extracellular matrix through the cell membrane. Dystrophin deficiency has been definitively established as one of the root-causes muscle dystrophy.

    Sentiment: Strong Buy

 
SRPT
31.85-0.15(-0.47%)11:52 AMEDT